Report of Foreign Issuer (6-k)
January 09 2017 - 6:06AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
January 2017
Commission file number: 001-36288
Akari Therapeutics, Plc
(Translation of registrant's name into English)
24 West 40
th
Street, 8
th
Floor
New York, NY 10018
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will
file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F
x
Form
40-F
¨
Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulations S-T Rule 101(b)(1):_____
Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulations S-T Rule 101(b)(7):_____
CONTENTS
Akari Therapeutics, Plc (the “Company”)
has posted to its website a corporate presentation. A copy of the presentation is furnished with this Report of Foreign Private
Issuer on Form 6-K as Exhibit 99.1 and is incorporated herein by reference.
The information contained in this report
(including the exhibit hereto) is hereby incorporated by reference into the Company’s Registration Statement on Form S-3,
File No. 333-207443.
Cautionary Note Regarding Forward-Looking
Statements
The presentation attached hereto as Exhibit
99.1 may contain forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities
Litigation Reform Act of 1995 and other Federal securities laws. These forward-looking statements reflect our current views about
our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and
on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected
in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations
or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking
statements and will be affected by a variety of risks and factors that are beyond our control. Such risks and uncertainties for
our company include, but are not limited to: an inability or delay in obtaining required regulatory approvals for Coversin and
any other product candidates, which may result in unexpected cost expenditures; risks inherent in drug development in general;
uncertainties in obtaining successful clinical results for Coversin and any other product candidates and unexpected costs that
may result therefrom; failure to realize any value of Coversin and any other product candidates developed and being developed in
light of inherent risks and difficulties involved in successfully bringing product candidates to market; inability to develop new
product candidates and support existing product candidates; the approval by the FDA and EMA and any other similar foreign regulatory
authorities of other competing or superior products brought to market; risks resulting from unforeseen side effects; risk that
the market for Coversin may not be as large as expected; inability to obtain, maintain and enforce patents and other intellectual
property rights or the unexpected costs associated with such enforcement or litigation; inability to obtain and maintain commercial
manufacturing arrangements with third party manufacturers or establish commercial scale manufacturing capabilities; the inability
to timely source adequate supply of our active pharmaceutical ingredients from third party manufacturers on whom the company depends;
our inability to obtain additional capital on acceptable terms, or at all; unexpected cost increases and pricing pressures; uncertainties
of cash flows and inability to meet working capital needs; and risks and other risk factors detailed in our public filings with
the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K filed on March 23, 2016. Except as otherwise
noted, these forward-looking statements speak only as of the date of the presentation and we undertake no obligation to update
or revise any of these statements to reflect events or circumstances occurring after this presentation. We caution investors not
to place considerable reliance on the forward-looking statements contained in this presentation.
Exhibit No.
|
99.1
|
Investor Presentation of
Akari Therapeutics, Plc dated January 2017.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
Akari Therapeutics, Plc
|
|
|
(Registrant)
|
|
|
|
|
|
|
By:
|
/s/ Robert M. Shaw
|
|
|
Name:
|
Robert M. Shaw
|
|
|
General Counsel & Secretary
|
|
Date: January 9, 2017
Akari Therapeutics (NASDAQ:AKTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Akari Therapeutics (NASDAQ:AKTX)
Historical Stock Chart
From Sep 2023 to Sep 2024